Your session is about to expire
← Back to Search
Vorinostat + Rituximab + Chemotherapy for Diffuse Large B-Cell Lymphoma
Study Summary
This trial is studying the side effects and best dose of vorinostat when given with rituximab and chemotherapy to treat patients with newly diagnosed stage II-IV diffuse large B-cell lymphoma.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2011 Phase 3 trial • 661 Patients • NCT00128102Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had chemotherapy, radiation, or antibody therapy for lymphoma.I can take care of myself and am up and about more than 50% of my waking hours.I do not have HIV.My tests show no lymphoma in my brain or spinal cord.My heart's pumping ability is normal, confirmed by a heart scan within the last 42 days.I haven't taken valproic acid in the last 28 days.I have a confirmed diagnosis of advanced DLBCL with a risk score above 0.My cancer can be measured and was checked by a CT or PET/CT scan within the last 28 days.I had a bone marrow test within the last 42 days.I have no cancer history except for certain skin cancers, early-stage cancers, or any cancer I've been free from for 5 years.I can provide a biopsy sample from my initial diagnosis for review.I am not pregnant or nursing and will use effective birth control if of reproductive age.I am willing to stop taking any medications that may cause heart rhythm problems during the study.My white blood cell count is healthy, not due to cancer in my bone marrow.
- Group 1: Treatment (combination chemotherapy)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there any vacancies in this experiment for volunteers?
"This trial has suspended its search for new candidates. It was initially put up on November 15th 2010 and last updated on the 16th of November 2022. If you are looking for other clinical trials, there is currently an abundance with 1782 studies searching for participants suffering from lymphoma or non-hodgkin's and 1528 research initiatives seeking volunteers to be administered Vorinostat."
To what maladies does Vorinostat typically offer a therapeutic solution?
"For patients with pheochromocytomas, Vorinostat is a common therapeutic option. Additionally, this pharmacological treatment can be used to treat ulcerative colitis and multiple myeloma, as well as varicella-zoster virus acute retinal necrosis."
How widely spread is the implementation of this research project?
"This trial is being conducted in 100 different medical centres, such as City of Hope Comprehensive Cancer Center (Duarte), Kalispell Regional Medical Center (Kalispell) and AdventHealth Hendersonville (Hendersonville)."
Are there any other studies which have explored the potential of Vorinostat?
"Vorinostat first appeared on the medical scene in 1993 at National Institutes of Health Clinical Center. Since then, 3266 clinical trials have been conducted and there are currently 1528 active studies across several cities, with a particular focus on Duarte, California."
How many enrollees are participating in this medical examination?
"At the present moment, this clinical trial is not taking on any new participants. The study was initially posted in November of 2010 and last updated in 16th of November 2022. If you're searching for alternatives, there are currently 1782 trials for lymphoma or non-hodgkin actively recruiting patients as well as 1528 studies with vorinostat accepting enrollees."
Share this study with friends
Copy Link
Messenger